Nov. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported third quarter 2024 financial results and ...
Analysts are estimating that Seres Therapeutics will report an earnings per share (EPS) of $-0.24. Seres Therapeutics bulls ...
Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript Seres Therapeutics jumps on report of Nestle acquisition ...
On Monday, Seres Therapeutics Inc (MCRB) stock saw a decline, ending the day at $0.81 which represents a decrease of $-0.01 or -1.22% from the prior close of $0.82. The stock opened at $0.83 and ...
Salarius Pharmaceuticals Inc (SLRX) is expected to report for 3Q. Seres Therapeutics Inc (MCRB) is expected to report $-0.08 for 3Q. Sonida Senior Living Corp (SNDA) is expected to report $-0.18 for ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
On Tuesday, Seres Therapeutics Inc (MCRB) stock saw a modest uptick, ending the day at $0.77 which represents a slight increase of $0.07 or 10.00% from the prior close of $0.7. The stock opened at $0.
Short interest in Seres Therapeutics Inc (NASDAQ:MCRB) increased during the last reporting period, rising from 15.94M to 17.22M. This put 15.76% of the company's publicly available shares short.
Oppenheimer analyst Jeff Jones maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report) today and set a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback